Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia (Q36911647)

17 August 2017

1 reference

title

Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia (English)

1 reference

17 August 2017

1 reference

3

Giovanni Martinelli

1 reference

17 August 2017

Pier Paolo Piccaluga

1

1 reference

PubMed ID

17701954

17 August 2017

Stefania Paolini

series ordinal

2

1 reference

PubMed ID

17701954

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

17 August 2017

1 reference

17 August 2017

110

1 reference

17 August 2017

6

1 reference

17 August 2017

1178-1186

1 reference

Tyrosine kinase - Role and significance in Cancer.

17 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

Loss of response to imatinib: mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Recent approaches in acute lymphoblastic leukemia in adults

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Acute lymphoblastic leukemia in elderly patients the Philadelphia chromosome may not be a significant adverse prognostic factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Improved treatment outcome in adult acute lymphoblastic leukemia using the intensive German protocol, a preliminary report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Philadelphia chromosome-positive acute lymphoblastic leukemia in Taiwan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Acute lymphoblastic leukemia in the elderly: The Edouard Herriot Hospital experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Imatinib: a selective tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Strategies to overcome resistance to targeted protein kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22881

7 January 2021

Identifiers

DOI

10.1002/CNCR.22881

1 reference

17 August 2017

1 reference

PubMed ID

17701954